Theravance Biopharma held an extraordinary general meeting on Sept. 18, 2026 to vote on merger-related resolutions.
- The meeting approved a special resolution authorizing the merger agreement and related transaction documents, including the plan of merger.
- The resolution also authorized amendments to the company’s memorandum and articles, plus an increase in authorized share capital tied to the merger structure.
- A separate advisory resolution on merger-related executive compensation was approved.
- The votes authorized the transactions but did not confirm completion or closing of the merger.
TBPH•
